Trial Profile
A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2020
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Doxorubicin; Pegfilgrastim
- Indications Leiomyosarcoma
- Focus Therapeutic Use
- 31 May 2020 Updated results of progression-free survival (PFS) and final results of overall survival (OS) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 14 May 2020 According to a PharmaMar media release, data from this trial will be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29th to June 2nd , 2020.
- 15 May 2014 A results of this study assessing the association between febrile neutropenia and skeletal muscle mass (SMM) and skeletal muscle densities (SMD) presented at the 2014 Annual Meeting of the ASCO, according to a PharmaMar media release.